DEF: Scholar Rock 2026 Annual Meeting Proxy Statement

Scholar Rock Holding Corporation schedules its 2026 Annual Meeting of Stockholders for June 4, 2026, to address director elections, auditor ratification, and executive compensation.

Summary

• The 2026 Annual Meeting of Stockholders will be held virtually on June 4, 2026, at 12:00 noon ET.
• Stockholders of record as of April 10, 2026, are entitled to vote.
• Proposal 1: Election of four Class II directors (David Hallal, Kristina Burow, Michael Gilman, and Katie Peng).
• Proposal 2: Ratification of Deloitte & Touche LLP as the independent registered public accounting firm for 2026.
• Proposal 3: Non-binding advisory vote on executive compensation.
• The company transitioned to a new executive leadership team in April 2025, including the appointment of David Hallal as CEO.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral, standard governance filing. While the leadership transition and new compensation structure are significant, they are typical for a company preparing for a major commercial launch.

Positives

• Successful transition to a new executive leadership team in 2025.
• Implementation of performance-based restricted stock units (PSUs) to align executive compensation with long-term stock price appreciation.
• Strong commitment to corporate governance, including the adoption of a Compensation Recovery Policy.
• The company has successfully engaged a new independent auditor, Deloitte & Touche LLP, following the resignation of Ernst & Young LLP.

Negatives

• The company is not yet a commercial-stage entity and has not generated revenue in 2023, 2024, or 2025.
• Significant executive turnover occurred in 2025, including the departure of former CEO Jay Backstrom.
• The company reported a net loss of $378 million in 2025.

Risks

• Risks related to the company's financial condition as a non-commercial stage entity.
• Dependence on successful development and commercialization of product candidates, specifically apitegromab.
• Cybersecurity risks and potential for data breaches.
• Intellectual property protection challenges.
• Potential for future dilution of shareholder value.

Future Outlook

The company is focused on the anticipated U.S. commercial launch of apitegromab for patients with spinal muscular atrophy (SMA) and establishing global brand strategy and market positioning.

Management Comments

• The Board believes that combining the roles of Chairman and CEO is appropriate given David Hallal's deep knowledge of the company and strategy.
• The Board believes that the new executive compensation structure, including PSUs, strongly aligns executive incentives with long-term stockholder interests.

Industry Context

StockSavvy.ai notes that Scholar Rock is navigating a critical transition from an R&D-focused organization to a commercial-stage company, a common but high-risk phase for biotech firms. The leadership overhaul in 2025 reflects a strategic pivot to prepare for the commercial launch of its lead asset, apitegromab, aligning with broader industry trends where companies bring in experienced commercial leadership to manage product launches.

Comparison to Industry Standards

• The company's peer group includes established biotech/pharma companies like Agios, Apellis, and Denali Therapeutics.
• The compensation structure, including the use of PSUs tied to stock price targets, is consistent with current market practices for late-stage clinical or early commercial-stage biotechnology companies.

Management Changes

Corporate Governance

Legal Proceedings

• No material legal proceedings adverse to the company are disclosed.

Related Party Transactions

• Participation of major stockholders (FMR LLC, T. Rowe Price, Redmile Group) in the October 2024 underwritten offering.

Stakeholder Impact

• Shareholders are asked to vote on key governance and compensation matters.
• The company's transition to commercial operations is intended to create long-term value for shareholders.

Next Steps

• Hold the 2026 Annual Meeting of Stockholders on June 4, 2026.
• File final voting results in a Form 8-K within four business days after the meeting.
• Continue commercial preparation for apitegromab.

Key Dates

Recommendation

The filing is a standard annual proxy statement. While it details a significant leadership change and new compensation structures, these are operational updates rather than immediate catalysts for a major share price move. Investors should hold and monitor the progress of the apitegromab commercial launch.

Keywords

Scholar Rock, SRRK, Proxy Statement, Biotechnology, Executive Compensation, Corporate Governance, Annual Meeting